Blurbs

Analysts Conflicted on These Healthcare Names: Cytokinetics (CYTK), McKesson (MCK) and uniQure (QURE)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cytokinetics (CYTKResearch Report), McKesson (MCKResearch Report) and uniQure (QUREResearch Report).

Cytokinetics (CYTK)

In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on Cytokinetics, with a price target of $82.00. The company’s shares closed last Thursday at $39.75.

According to TipRanks.com, Butler is ranked 0 out of 5 stars with an average return of -8.3% and a 38.2% success rate. Butler covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, ACADIA Pharmaceuticals, and Aquestive Therapeutics.

Cytokinetics has an analyst consensus of Strong Buy, with a price target consensus of $71.13, a 72.1% upside from current levels. In a report issued on October 21, Mizuho Securities also maintained a Buy rating on the stock with a $80.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

McKesson (MCK)

In a report issued on November 1, Ann Hynes from Mizuho Securities maintained a Hold rating on McKesson, with a price target of $345.00. The company’s shares closed last Thursday at $397.58, close to its 52-week high of $399.42.

According to TipRanks.com, Hynes is a 5-star analyst with an average return of 8.3% and a 59.7% success rate. Hynes covers the Healthcare sector, focusing on stocks such as Edwards Lifesciences, Intuitive Surgical, and Quest Diagnostics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for McKesson with a $415.55 average price target, representing a 7.2% upside. In a report issued on November 2, Barclays also maintained a Hold rating on the stock with a $415.00 price target.

uniQure (QURE)

SVB Securities analyst Joseph Schwartz reiterated a Buy rating on uniQure on November 2 and set a price target of $56.00. The company’s shares closed last Thursday at $19.67.

According to TipRanks.com, Schwartz is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -16.9% and a 30.3% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Crinetics Pharmaceuticals, and Mereo Biopharma Group Plc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for uniQure with a $52.33 average price target, a 164.6% upside from current levels. In a report released yesterday, Goldman Sachs also maintained a Buy rating on the stock with a $48.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CYTK:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More